Sofwave Medical has received approval from the US Food and Drug Administration (FDA) for its synchronous ultrasound parallel beam (SUPERB) technology for the short-term improvement in cellulite appearance.

The technology has been designed to address the increasing demand for non-invasive treatments.

It comprises cooled transducers which are coupled to the epidermis directly. This creates a 3D array of volumetric thermal zones to provide parallel energy simultaneously.

The company stated that a single treatment with the technology is capable of reducing facial wrinkles in 30 to 45 minutes without interruption to a patient’s daily routine.

As part of the 510(k) application, Sofwave Medical has submitted data from clinical trials to support the FDA clearance in cellulite.

It has also conducted a multi-site clinical study that assessed the device’s safety and effectiveness for the non-invasive dermatological aesthetic improvement in cellulite appearance.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In the study, 68 women were treated at four sites in the US and the eligible participants received two treatments using SUPERB technology on the right or left of the lateral/posterior upper thigh or buttocks.

To evaluate the subjects, serial clinical photographs were taken under standardised conditions prior to treatment as well as at the three-month follow-up visits.

Blinded independent reviewers assessed the photos to spot the pre-treatment images when compared to post-treatment images.

Using the Cellulite Severity Scale (CSS), the reviewers also graded the pre-treatment and post-treatment images.

They correctly identified the post-treatment images in 89% of the participants in the post-study.

Sofwave Medical CEO Lou Scafuri said: “The FDA’s clearance of SUPERB for use in cellulite could not have come at a timelier moment.

“Our dedicated US direct sales force is positioned to expand our growing presence and market share of the aesthetic medical device market in the US.

“In addition, our recent regulatory clearance in Brazil further extends our global footprint, letting us immediately launch sales in this important and sizeable market.”